Business
Satellos Bioscience Announces Appointment of Chief Medical Officer
Dr. Alan K. Jacobs joins Satellos as CMO on June 7th, 2023 Toronto, Ontario--(Newsfile Corp. - J...
About this update from Satellos Bioscience Inc
[{"type":"text","content":"Satellos Bioscience Announces Appointment of Chief Medical OfficerDr. Alan K. Jacobs joins Satellos as CMO on June 7th, 2023Toronto, Ontario--(Newsfile Corp. - June 7, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (\"Satellos\" or the \"Company\"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today the appointment of Alan K. Jacobs, MD as Chief Medical Officer (CMO) of the Company, effective June 7, 2023.\"Dr. Jacobs is an accomplished and experienced clinical development professional with an extensive and impressive track record in both early and late-stage therapeutic development in the neuroscience and rare disease spaces,\" says Frank Gleeson, Chief Executive Officer, Satellos Bioscience. \"We are delighted to have Dr. Jacobs' clinical leadership on the Satellos team where he will play a lead role in planning and executing clinical trials to advance our novel medicines commencing with Duchenne muscular dystrophy.\" Dr. Jacobs joins Satellos from Boston Pharmaceuticals, where as Vice President, Clinical Development, Neuroscience he oversaw early and late-stage development programs, led integrated development and biomarker plan creation, created and oversaw clinical trials, and contributed to business development collaborations. Prior to that he held progressively senior leadership roles with Immunovant and Sanofi Genzyme, including strategic coordination of multiple successful IND submissions and development and execution of Phase 2 and 3 clinical trials. Previously, Dr. Jacobs was Medical Director with both the Ohio Center for Treatment and Research in Multiple Sclerosis and the Center for Neuroscience Research in Dayton, Ohio. He was concurrently a Professor of Neurology at the Wright State University Boonshoft School of Medicine. Dr. Jacobs is a Fellow of the American Academy of Neurology.\"Satellos is doing incredibly important work and is well-positioned in its mission to advance the treatment of Duchenne muscular dystrophy and other muscle diseases of high unmet need,\" says Dr. Jacobs, who has acted as Principal Investigator on nearly 100 clinical studies in the neurosciences over the course of his career. Continued Dr. Jacobs, \"I'm so looking forward to joining such an innovative team and applying my expertise in clinical deve...